TNXP — Tonix Pharmaceuticals Holding Cashflow Statement
0.000.00%
Last trade - 00:00- $179.13m
- -$28.51m
- $13.11m
Annual cashflow statement for Tonix Pharmaceuticals Holding, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -92.3 | -110 | -117 | -130 | -124 |
| Depreciation | |||||
| Non-Cash Items | 10.9 | 10.9 | 10.4 | 59.9 | 10.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.78 | -0.002 | -0.035 | 5.78 | 11.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -75.6 | -98.1 | -102 | -60.9 | -99.8 |
| Capital Expenditures | -35.3 | -48.1 | -7.89 | -0.12 | -3.37 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -21.2 | — | -1.16 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -35.3 | -48.1 | -29.1 | -0.12 | -4.53 |
| Financing Cash Flow Items | — | — | — | -3 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 212 | 87.8 | 36.5 | 135 | 215 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 102 | -58.4 | -94.6 | 73.8 | 110 |